Trial reportJournal of clinical periodontology2025
Systemic Azithromycin as an Adjunct to Non-Surgical Subgingival Instrumentation in the Treatment of Stage III/IV, Grade C Periodontitis: 12-Month Clinical, Microbiological and Cytokine Results of a Randomised Controlled Trial.
Trial report in Journal of clinical periodontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Systemic Antibiotics as Adjuncts in Periodontal Therapy for Stage III and Stage IV Periodontitis: An Umbrella Review Aligned with the 2018 World Workshop Classification, with AMSTAR-2 Critical Appraisal.Antibiotics (Basel, Switzerland) · 2026Review
- Azithromycin in Dentistry: From Systemic Antibiotic to a Candidate for Local Therapeutic Delivery.Pharmaceutics · 2026Review
- Local drug delivery systems for the periodontal microenvironment: from barrier penetration to multilevel synergy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo evaluate the clinical, microbial and cytokine changes following the use of oral azithromycin as an adjunct to non-surgical subgingival instrumentation (NSI) in stage III/IV, grade C periodontitis through a triple-blind, parallel-armed, randomised controlled trial. MATERIAL AND
methodsA total of 52 patients with stage III/IV grade C periodontitis were randomly allocated to two groups receiving NSI with or without adjunctive azithromycin. The primary outcome was changes in the periodontal inflamed surface area (PISA) values over 12 months, and the secondary outcomes included changes in pocket depth (PD), clinical attachment loss (CAL), percentage of sites with PD of 1-3, 4-5, ≥ 5 and ≥ 6 mm, subgingival periodontal pathogens, cytokine levels and patient-reported outcomes.
resultsAt 3 and 12 months, there were no statistically significant differences in the reduction in PISA or other clinical parameters between the groups. At 3 months, the levels of several periodontal pathogens were significantly reduced in the azithromycin group. No significant differences were observed in the levels of periodontal pathogens at 12 months except for Prevotella intermedia. No significant differences were observed for the studied cytokines at 3 and 12 months.
conclusionThe results of this study do not support the use of systemic azithromycin in stage III/IV, grade C periodontitis.
trial registrationThe trial was registered prospectively in the Australia New Zealand Clinical Trial Registry, ACTRN12619000560190. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374699.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.